ATE277620T1 - Neue formulierungen zur transdermale verabreichung von fluoxetinacetat und fluoxetinmaleat - Google Patents

Neue formulierungen zur transdermale verabreichung von fluoxetinacetat und fluoxetinmaleat

Info

Publication number
ATE277620T1
ATE277620T1 AT97932610T AT97932610T ATE277620T1 AT E277620 T1 ATE277620 T1 AT E277620T1 AT 97932610 T AT97932610 T AT 97932610T AT 97932610 T AT97932610 T AT 97932610T AT E277620 T1 ATE277620 T1 AT E277620T1
Authority
AT
Austria
Prior art keywords
fluoxetine
transdermal administration
acetate
composition
maleate
Prior art date
Application number
AT97932610T
Other languages
English (en)
Inventor
Robert M Gale
Melinda K Nelson
Michel J N Cormier
Suneel K Gupta
Patricia S Campbell
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE277620T1 publication Critical patent/ATE277620T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT97932610T 1996-07-15 1997-07-15 Neue formulierungen zur transdermale verabreichung von fluoxetinacetat und fluoxetinmaleat ATE277620T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2172796P 1996-07-15 1996-07-15
PCT/US1997/012335 WO1998002169A2 (en) 1996-07-15 1997-07-15 Novel formulations for the administration of fluoxetine

Publications (1)

Publication Number Publication Date
ATE277620T1 true ATE277620T1 (de) 2004-10-15

Family

ID=32848735

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97932610T ATE277620T1 (de) 1996-07-15 1997-07-15 Neue formulierungen zur transdermale verabreichung von fluoxetinacetat und fluoxetinmaleat
AT03022248T ATE322272T1 (de) 1996-07-15 1997-07-15 Neue formulierungen zur transdermale verabreichung von fluoxetin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03022248T ATE322272T1 (de) 1996-07-15 1997-07-15 Neue formulierungen zur transdermale verabreichung von fluoxetin

Country Status (7)

Country Link
EP (1) EP0946184B1 (de)
AT (2) ATE277620T1 (de)
AU (1) AU3601897A (de)
CY (1) CY2503B1 (de)
DE (2) DE69730988T2 (de)
ES (2) ES2259746T3 (de)
WO (1) WO1998002169A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013740A1 (en) * 1998-03-27 2003-01-16 Martin P. Redmon Stable dosage forms of fluoxetine and its enantiomers
ES2261190T3 (es) † 1999-02-08 2006-11-16 Alza Corporation Vehiculos viscosos no acuosos estables de fase unica y formulaciones que utilizan dichos vehiculos.
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
WO2004030618A2 (en) * 2002-09-24 2004-04-15 Combinatorx, Incorporated Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2007117581A2 (en) * 2006-04-06 2007-10-18 Collegium Pharmaceutical, Inc. Stabilized transdermal bupropion preparations
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP3735944A1 (de) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411738A (en) * 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
WO1992019241A1 (en) * 1991-05-07 1992-11-12 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
AU6410494A (en) * 1993-03-17 1994-10-11 Alza Corporation Device for the transdermal administration of alprazolam
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
WO1997010816A1 (en) * 1995-09-22 1997-03-27 Eli Lilly And Company METHODS OF TREATING β-AMYLOID-ASSOCIATED CONDITIONS

Also Published As

Publication number Publication date
AU3601897A (en) 1998-02-09
WO1998002169A2 (en) 1998-01-22
EP0946184A2 (de) 1999-10-06
DE69735656T2 (de) 2006-08-24
HK1063148A1 (en) 2004-12-17
DE69730988T2 (de) 2006-02-23
WO1998002169A3 (en) 1998-03-12
CY2503B1 (en) 2005-09-02
ES2227707T3 (es) 2005-04-01
DE69735656D1 (de) 2006-05-18
EP0946184B1 (de) 2004-09-29
DE69730988D1 (de) 2004-11-04
ATE322272T1 (de) 2006-04-15
ES2259746T3 (es) 2006-10-16

Similar Documents

Publication Publication Date Title
ATE277620T1 (de) Neue formulierungen zur transdermale verabreichung von fluoxetinacetat und fluoxetinmaleat
DE69637061D1 (de) Neue formulierungen zur transdermalen verabreichung von pergolid
US4746515A (en) Skin permeation enhancer compositions using glycerol monolaurate
US4568343A (en) Skin permeation enhancer compositions
JP3688293B2 (ja) モノグリセリド／乳酸エステル透過促進剤
US4900555A (en) Skin permeation enhancer compositions using sucrose esters
KR900701274A (ko) 남용 가능성을 감소시킨 용량 제형
MX9709162A (es) Composiciones mejoradas de la permeacion en la piel que usan lactilatos de acilo.
TW366286B (en) Flavour-masked pharmaceutical compositions
NO944249L (no) Transdermal administrering av oksybutynin
DK0934078T3 (da) Permeabilitetsfremmere til transdermal administrering af aktivstoffer, anordninger og fremgangsmåde til fremstilling deraf
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
ATE248511T1 (de) Zusammensetzung zur zielortspezifischen verabreichung eines medikamentes und verfahren zur anwendung
JP2002535293A5 (de)
JPH0640947A (ja) 経皮吸収製剤用組成物および経皮吸収製剤
ES2184561A1 (es) Forma farmaceutica solida de administracion oral dispersable en agua para el tratamiento de la tuberculosis conteniendo refampicina, isoniazida, pirazinamida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
CA2333076A1 (en) Topical application of muscarinic analgesic drugs such as neostigmine
ATE228843T1 (de) Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit
DE69918124T2 (de) Zusammensetzungen und Vorrichtungen zur transdermalen Verabreichung von Fenoldopam
AU7576000A (en) Transdermal administration of n-(2,5-disubstituted phenyl)-n'-(3-substituted phenyl)-n'-methyl guanidines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0946184

Country of ref document: EP

REN Ceased due to non-payment of the annual fee